Compare GSK plc (GSK) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Symbotic Inc — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Symbotic Inc trades at $42.1 (market cap $5.42B). The key difference: GSK plc is far larger — about 18.7× Symbotic Inc's market cap, and GSK plc pays a 3.49% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| GSK | SYM | |
|---|---|---|
Market Cap | $101.34B | $5.42B |
Sector | Health | Technology |
52-Week High | $61.18 | $87.30 |
52-Week Low | $36.20 | $38.57 |
Enterprise Value | $121.95B | $3.42B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SYM trades at $43.00, down 1.51% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported $2.25B revenue for 2025 but posted a net loss of $16.94M, though margins show improvement. Recent news highlights Symbotic's acquisition of ARMS Innovations and strong positioning in warehouse automation, with Amazon's robotics expansion potentially benefiting the company.
Analysts maintain a bullish consensus with a $57.50 price target (61% buy ratings), but near-term risks include negative profitability, high valuation multiples (EV/EBITDA 231.28), and competitive pressures. The stock faces technical resistance at $44-46 while testing support at $40-42, requiring improved earnings execution to justify current valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
